SCHEMBL13060218

SCHEMBL13060218

CC(C)(C)OC(=O)N1CC(/C=C/CN2CCC(F)(C(=O)N3CCC(Oc4cc(C(F)(F)F)sc4C#N)CC3)CC2)C1

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.36
PDE4B Q07343 6/20 0.34
PDE4D Q08499 4/20 0.34
PDE4A P27815 3/20 0.34
PDE4C Q08493 3/20 0.34
KDM1A O60341 1/20 0.33
BRD4 O60885 1/20 0.32
ALK Q9UM73 1/20 0.30
TBK1 Q9UHD2 1/20 0.30
P2RX3 P56373 1/20 0.30
P2RX2 Q9UBL9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13003975 0.88
SCHEMBL14624410 0.87 HRH3 (0.31)
SCHEMBL13060217 0.87 GPR119 (0.44) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL13060409 0.80 GPR119 (0.51) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL13588430 0.77 KDM1A (0.45) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL13003974 0.76 BCL9 (0.33) GPR119
SCHEMBL13060192 0.68 PDE4D (0.48) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL14624556 0.68 PDE4D (0.50) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL13060448 0.67 PDE4D (0.50) GPR119PDE4BPDE4DPDE4APDE4C
SCHEMBL13060447 0.66 PDE4D (0.49) GPR119PDE4BPDE4DPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846946-B2 Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists SCHERING PLOUGH CORPORATION (US) 2010-12-07 US disclosed
US-7635705-B2 treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders; histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-22 US disclosed
US-20090286830-A1 HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS SCHERING CORPORATION 2009-11-19 US disclosed
US-20070015807-A1 Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015807-A1 Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists HRH3, HRH4, CHRM2 GPR119 44/4885PDE4B 4732/4885PDE4D 4824/4885
US-20090286830-A1 HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS HRH3, HRH4, CHRM2 GPR119 44/4885PDE4B 4732/4885PDE4D 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.